Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.51 USD
Change Today +0.08 / 18.60%
Volume 150.1K
DMPI On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

delmar pharmaceuticals inc (DMPI) Snapshot

Open
$0.48
Previous Close
$0.43
Day High
$0.51
Day Low
$0.44
52 Week High
09/19/14 - $1.03
52 Week Low
08/27/15 - $0.43
Market Cap
21.9M
Average Volume 10 Days
28.3K
EPS TTM
--
Shares Outstanding
42.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELMAR PHARMACEUTICALS INC (DMPI)

Related News

No related news articles were found.

delmar pharmaceuticals inc (DMPI) Related Businessweek News

No Related Businessweek News Found

delmar pharmaceuticals inc (DMPI) Details

DelMar Pharmaceuticals, Inc. focuses on the discovery and development of medicines with the potential to treat cancer patients who have failed modern targeted or biologic therapy. Its principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China. DelMar Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

4 Employees
Last Reported Date: 07/15/15
Founded in 2010

delmar pharmaceuticals inc (DMPI) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $72.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $60.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2014.

delmar pharmaceuticals inc (DMPI) Key Developments

DelMar Pharmaceuticals, Inc. Announces Update on its Phase I/II Clinical Trial of VAL-083

DelMar Pharmaceuticals Inc. announced that the company will be presenting updated clinical data on its lead product candidate, VAL-083, from its Phase I/II clinical trial in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer. DelMar's abstract entitled, ‘Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma,’ will be presented during a poster session at GBM2015, II International Symposium on Clinical and Basic Investigation in Glioblastoma, being held September 9 - 12, 2015, in Toledo, Spain. In spite of recent advances in cancer care, GBM continues to be the most common and malignant primary brain tumor in adults carrying a dismal prognosis with less than 15 months median survival. The symposium is designed with a focus on clinical and basic research in this devastating disease. DelMar recently presented interim data from the trial at the American Association of Clinical Oncology (ASCO) Annual meeting. The Company confirmed the completion of the Phase I dose-escalation portion of the trial and presented data supporting a dose response trend:  Patients receiving a dose =30mg/m2 had a median survival of 9.0 months vs. 4.4 months at doses <10mg/m2. DelMar also confirmed the initiation of a 14-patient Phase II expansion cohort at a dose of 40mg/m2. The purpose of the Phase II expansion cohort is to gain additional information about the safety and efficacy of VAL-083 at the 40mg/m2 dose prior to advancement into registration-directed Phase II/III clinical trials. DelMar's multicenter Phase I/II clinical study with VAL-083 is ongoing in patients with recurrent GBM. Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. VAL-083 is a "first-in-class", small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas. DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme (GBM) in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA). As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).

Del Mar Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM

Del Mar Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO

Del Mar Pharmaceuticals Inc. announced updated clinical data from its Phase I/II clinical trial of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer. The study was designed to assess the safety and tolerability of patients receiving VAL-083 on days 1, 2, and 3 of a 21-day cycle. Tumor response is assessed according to RANO criteria prior to every other 21-day treatment cycle, and patients exhibiting stable disease or tumor regression at the first scan following treatment were allowed to continue treatment with VAL-083 at the dose defined for their cohort. Determination of maximum tolerated dose (MTD) is based on a 3+3 design. Currently, 30 GBM patients have been enrolled across 8 dose cohorts ranging from 1.5 to 50mg/m2/d. All GBM patients enrolled in DelMar's Phase I/II clinical trial failed prior treatment with standard front-line (temozolomide plus radiation) and 92% also failed Avastin. Seventy-seven percent also failed one or more courses of additional salvage therapy beyond temozolomide and Avastin prior to VAL-083. Patients were not re-resected prior to treatment with VAL-083 and therefore have a growing GBM tumor at the time of enrollment in the DelMar clinical trial. O6-methylguanine methyltransferase (MGMT) expression was characterized for patients whose data or tissue blocks were available for analysis. All patients whose tumors were characterized had an unmethylated MGMT promotor, which is correlated with poor patient outcomes to currently available therapies. 30 GBM patients were treated with escalating doses of VAL-083 ranging from 1.5m/m2 to 50mg/m2 in a regimen of daily treatment x 3 days in a 21 day cycle. Patients receiving a dose >30mg/m2 daily x 3 every 21 days had a median survival of 9.0 months vs. 4.4 months at doses <10mg/m2 daily x 3 every 21 days, demonstrating a dose-response trend. Median number of treatment cycles of VAL-083 = 2.0. Median Progression Free Survival (PFS) was short (1.2 – 1.4 months). Adverse events were typically mild to moderate; no treatment-related serious adverse events at doses up to 40mg/m2 daily x 3 every 21 days were observed. Dose limiting toxicity (DLT) was observed in two of six (33%) of patients at 50mg/m2 daily x 3 every 21 days. Pharmacokinetic analysis suggests that a dose of 40mg/m2 achieves concentrations of VAL-083 in the CNS at or above the IC50 observed for multiple GBM cell lines in vitro.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMPI:US $0.51 USD +0.08

DMPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMPI.
View Industry Companies
 

Industry Analysis

DMPI

Industry Average

Valuation DMPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 18.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELMAR PHARMACEUTICALS INC, please visit www.delmarpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.